You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
朗生醫藥(00503.HK)上半年期內溢利達680萬美元 同比上升約344.5%
格隆匯 08-31 21:37

格隆匯8月31日丨朗生醫藥(00503.HK)公佈,截至2022年6月30日止6個月,朗生錄得收入約3200萬美元,較去年同期上升約36.2%。集團的收入升幅主要由於集團主要產品帕夫林和新適確得在本期的銷售量較去年同期上升。由於收入上升,導致毛利相應上升,期內經營溢利約920萬美元,較去年同期上升約229.6%,而期內溢利約達680萬美元,較去年同期上升約344.5%。

然而,管理層相信2022年上半年表面上較好的業績表現並不代表公司的業務大幅改善。而是主要由於以下原因:

1.集團於2021年關注到主要產品銷售量下降的情況,並於2021年調整銷售策略並逐步實施。從經營角度來看,管理層認為重組管理架構及銷售策略調整顯現初步效果,集團的業績表現只是在恢復軌道上。

集團銷售市場相關活動在2022年上半年受疫情影響未能按計劃全面開展,預計2022年下半年隨着遞延的銷售市場活動陸續恢復,銷售市場費用支出預期比2022年上半年將有所增加。另外疫情管控政策實施也可能會對集團下半年業務達成產生影響,因此我們對於集團全年的業績前景仍持謹慎態度。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account